Company intelligence / Profile preview
KBP Biosciences
Princeton, New Jersey, United Stateskbpbio.com ↗
- Ownership
- Private
- Employees
- ~47
- Development stage
- Other
01
Overview
KBP Biosciences is a global clinical-stage biopharmaceutical company developing innovative small molecule therapies targeting unmet needs in organ protection and infectious diseases. Its lead program was ocedurenone (KBP‑5074), a third-generation non-steroidal mineralocorticoid receptor antagonist developed for uncontrolled hypertension and cardiorenal disease in CKD patients. The asset was acquired by Novo Nordisk but failed its pivotal Phase 3 trial. The company maintains an integrated R&D platform supporting additional preclinical and clinical programs across multiple therapeutic areas.
- Therapeutic areas
- ImmunologyCardiovascularInfectious DiseasesNephrology
- Modalities
- Small molecules (notably new chemical entities with known mechanisms of action)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Novo Nordisk previously acquired rights to ocedurenone from KBP Biosciences via an up-to-$1.3 billion deal before terminating the program post-phase III failure.
Beyond the preview
Go deeper on KBP Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBP Biosciences.